UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
April 1, 2009
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
RESEARCH UPDATE
LIRAGLUTIDE BRIEFING DOCUMENTS NOW AVAILABLE FOR THE FDA ADVISORY COMMITTEE
MEETING ON 2 APRIL
Novo Nordisk announced today that the United States Food and Drug Administration
(FDA) has made liraglutide briefing documents publicly available on its website
(www.fda.gov) ahead of the Endocrinologic and Metabolic Drugs Advisory Committee
public meeting on 2 April 2009. This is a common procedure in connection with
advisory committee meetings.
The briefing documents from Novo Nordisk and the FDA provide an overview of the
non-clinical and clinical data for liraglutide in the treatment of type 2
diabetes and will form the basis for the Advisory Committee's discussion. The
Novo Nordisk briefing document contains data from 40 clinical studies involving
more than 6,800 people with type 2 diabetes of which more than 4,600 were
treated with liraglutide.
The Advisory Committee is expected to make recommendations to the FDA on
questions related to the approval of liraglutide for the treatment of type 2
diabetes based on the overall benefit:risk profile of liraglutide.
FDA advisory committees are panels of independent experts who advise the FDA as
they consider regulatory decisions.
CONFERENCE CALL
On 3 April at 8 am CET, corresponding to 2 am EDT, a conference call for
investors will be held. Investors will be able to listen in via a link on the
investor section of novonordisk.com.
ABOUT LIRAGLUTIDE
Liraglutide is the first once-daily human Glucagon-Like Peptide-1 (GLP-1)
analogue developed for the treatment of type 2 diabetes. Liraglutide works by
stimulating the release of insulin only when glucose levels become too high and
by inhibiting appetite. On 23 May 2008, Novo Nordisk submitted a New Drug
Application to the Food and Drug Administration in the US as well as a marketing
authorisation application to the European Medicines Agency in Europe, for the
approval of liraglutide for the treatment of people with type 2 diabetes. A New
Drug Application was also submitted for approval in Japan on 15 July 2008.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81
countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.
Contacts for further information:
Media: Investors:
Mike Rulis Mads Veggerby Lausten
Tel: (+45) 4442 3573 Tel: (+45) 4443 7919
mike@novonordisk.com mlau@novonordisk.com
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
krop@novonordisk.com
In North America: In North America:
An Phan Hans Rommer
Tel: (+1) 609 558 0420 Tel: (+1) 609 919 7937
anph@novonordisk.com hrmm@novonordisk.com
Company Announcement no 18 / 2009
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: April 1, 2009 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer